Daehwa receives U.S. PTO notice of allowance for oral paclitaxel

Daehwa said Wednesday that its patent application entitled “Solubilizing composition for paclitaxel and its manufacturing method” has received notice of allowance from the U.S. Patent and Trademark Office.

Paclitaxel is an anticancer agent widely applied in the treatment of advanced breast, lung and ovarian cancer. However, intravenous administration of paclitaxel is inconvenient to patients...